Colonoscopic Probiotics Spray in Irritable Bowel Syndrome

Launched by NATIONAL CHENG-KUNG UNIVERSITY HOSPITAL · May 16, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to treat irritable bowel syndrome (IBS), a common condition that causes symptoms like stomach pain and changes in bowel habits. Researchers are exploring the use of a probiotics spray, which is delivered directly into the colon through a procedure called colonoscopy. This method aims to deliver beneficial bacteria more effectively than traditional oral probiotics, potentially leading to better relief from IBS symptoms. Participants will be randomly assigned to either receive the probiotics spray or a placebo (a treatment with no active ingredients) during the study.

To be eligible for the trial, participants should have moderate to severe IBS symptoms, as measured by a specific scoring system. However, individuals with certain health conditions, such as immune deficiencies or severe psychiatric disorders, as well as pregnant or breastfeeding women, will not be able to take part. Throughout the study, participants can expect to receive treatment for four weeks and will be monitored for changes in their gut health and any side effects. This research could help improve future treatments for IBS, making life easier for those affected by this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Moderate-to-severe IBS symptoms, as indicated by a score of ≥175 on the IBS Severity Scoring System (IBS-SSS).
• Exclusion Criteria:
• • Presence of immune deficiency or treatment with immune-modulating medication.
• • Pregnant or lactating.
• • Severe psychiatric disorder, or alcohol or drug abuse.
• • Use of probiotics or treatment with antibiotics within 4 weeks prior to study entry.